Henderson Michael Thomas reported grant involving 8,026 derivative units of Spyre Therapeutics, Inc. at $0.00 for $0 on May 27, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
8,026Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
8,026Direct
Trade date
May 27, 2026Grant
Filed
May 29, 2026, 5:55 PM ET2-day reporting delay
Accession
0001636282-26-000067Code A · Transaction 93218
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

SYRE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
SYRE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −2.2%1w ago −2.1%1d ago +0.2%
Returns since7d +0.2%30d +20%90d180d1y

Footnotes in full

F1: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.